AcelRx names Vincent Angotti CEO and to board
Mr. Angotti brings over two decades of experience leading executive and commercial teams at public and private life sciences companies, most recently as CEO of XenoPort, Inc., a biopharmaceutical company focused on the development of treatments for neuropathic pain and other neurological disorders.
Mr. Angotti joined XenoPort, Inc. in 2008 as SVP and chief commercialization officer and was promoted to EVP and COO in 2012 and to CEO in 2015.
During his tenure at XenoPort, Mr. Angotti was involved in the re-acquisition of Horizant from GSK and implemented a successful re-branding and re-launch strategy leading to XenoPort's acquisition by Arbor Pharmaceuticals, LLC in 2016.
Previous to joining XenoPort, he held senior sales and marketing positions at Reliant Pharmaceuticals, Inc. from 2001 – 2008.
In his role as senior vice president of sales and marketing at Reliant, Mr. Angotti was integrally involved in the company's M&A discussions that concluded with Reliant's acquisition by GSK in 2007.
Mr. Angotti began his career in the life sciences industry at Novartis Pharmaceuticals Corp., where he worked from 1991 – 2001 in sales and operations positions of increasing responsibility.
He earned a Bachelor of Science with a concentration in business management from Cornell University in 1990 and a Masters of Business Administration with honors in 2000 from Columbia University.
Mr. Angotti succeeds Howie Rosen, who will continue on the AcelRx board of directors, where he has served since 2008. ■
What to read next
LATEST MOVES FROM California
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
- Amyris appoints Eduardo Alvarez as COO
- ChromaDex appoints Kevin Farr as CFO
More inside POST
Sinopec's net profit surges 40% Earnings